Baili Tianheng (688506.SH): Yizekang® included in the list of breakthrough treatment varieties

^{Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the world's first, new concept, and the world's first and only EGFR x HER3 double antibody ADC, Yizekang® (lencan elontuzumab, BL-B01D1/iza-Bren) for patients with recurrent or metastatic biliary tract cancer who have previously failed platinum-containing chemotherapy treatment has been included in the list of breakthrough treatments by the Drug Evaluation Center of the State Drug Administration (“Drug Review Center”). The announcement was recently completed.} . Up to now, 9 indications of Yizekang ^® have been included in the list of breakthrough treatment varieties by the Drug Review Center, and 1 indication has been certified as a breakthrough therapy by the US Food and Drug Administration.